LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Saliva Tests as Good as PCR Tests for Diagnosing COVID-19 in Early Phase of Infection

By LabMedica International staff writers
Posted on 11 Nov 2021
Print article
Illustration
Illustration

Researchers investigating whether rapid antigen testing can be used on saliva instead of swabbing the nasal cavity have found that saliva can be good enough for diagnosing COVID-19 in the early phase of infection.

The study from Lund University (Lund, Sweden) aimed to find out if rapid COVID-19 tests using saliva could be easier alternatives to the common PCR tests which involve a nose and throat sample taken with a cotton swab - a procedure that is often unpleasant. Quick diagnostic tools are crucial in reducing the spread of COVID-19. Today, there are several different test methods to identify an ongoing infection. The PCR tests used in healthcare and most commercially available antigen tests are usually taken with swabs in the nasal cavity - a method that many find uncomfortable. Antigen tests are used as a complement to PCR testing when increased test capacity or rapid test results are required. However, there are also saliva tests.

In the current study, the researchers compared RT-PCR tests with saliva samples they collected from 44 patients. All 44 participants had confirmed COVID-19, and had to clear their throat before spitting. The results showed that coronavirus can be detected in both saliva and nasal cavity samples, but that the concentrations are slightly lower in saliva. The researchers also examined four different rapid antigen tests available on the market, to see how well they detect the virus in saliva samples. All four antigen tests were found to be relatively sensitive in detecting the virus early in the infection, as the virus concentration is higher at that point. Later in the infection, when the virus concentration is lower, the antigen tests were not sufficiently sensitive. The researchers believe that rapid saliva tests are a good alternative to standard PCR testing, and can also supplement these methods as screening needs increase.

“Although our study isn’t definitive, our results indicate that rapid tests using saliva might be good enough for diagnosing COVID-19 in the early phase of infection”, said Magnus Rasmussen, specialist in infectious disease medicine at Skåne University Hospital and professor at Lund University, who led the study.

“The advantage of a saliva-based rapid test is that you can easily take it at home in peace and quiet. For many, it can make a big difference. If infection occurs in, for example, primary school, the younger unvaccinated students can be screened more quickly with a saliva-based rapid test. For children, it is important that sampling is simple and without discomfort”, added Yang de Marinis, who is the first author of the study.

Related Links:
Lund University 

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Centromere B Assay
Centromere B Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.